LAUNXP Biomedical Co., Ltd (TPEX: 6876)
Health Care · Pharmaceuticals · TW
NT$11.20
-10.76% today · -52.3% 1Y
LAUNXP Biomedical Co., Ltd (TPEX: 6876) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $11.36M and employs 35 people.
Over the last twelve months the share price has lost 52.3%, trading between 9.09 and 27.00.
6876 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.36M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- —
- Dividend yield
- —
- Beta (5Y)
- -0.12
- 52-week high
- NT$27.00
- 52-week low
- NT$9.09
- Avg volume (3M)
- —
- Shares outstanding
- 32.45M
- Employees
- 35
- Next earnings
- —
About LAUNXP Biomedical Co., Ltd
LAUNXP Biomedical Co. Ltd. specializes in developing innovative pharmaceutical treatments for various types of cancer. Their product line includes therapies designed to combat tumor growth and inhibit cell proliferation, notably utilizing advanced platforms such as virus-like nanoparticles and other nanoparticle-based drug delivery systems. The company was established on September 24, 2015, and its primary corporate operations are based in Taichung, Taiwan.
- ISIN
- TW0006876006
- Founded
- 2015
- Listed since
- Jan 18, 2024
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,257.82 | +0.87% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.14 | +0.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $153.92 | +2.16% |
| Roche Holding AGSWX: ROP | $368.80B | CHF373.60 | +0.86% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £123.85 | +2.27% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $28.35 | +1.34% |
Figures last refreshed Aug 18, 2026.